Journey Medical Corporation reported total revenues of $19.0 million for Q3 2026, an 8% increase from the previous year, driven by an 84% rise in sales of Emrosi®, its oral rosacea treatment. The company improved its gross margin to 69% and narrowed its GAAP net loss to $1.3 million from $2.3 million a year earlier. Positive EBITDA and adjusted EBITDA were achieved, supported by strong prescription demand and expanded sales efforts. With $22.3 million in cash, Journey Medical is positioned to continue growing its dermatology product portfolio and market presence.
Journey Medical Corporation's Q3 2026 results provide context for readers. For those tracking health-sector stocks, Pluang shows 23 of 150 US health stocks rose, 124 fell as of Nov 13, 2026 04:11 WIB. Notable movers include IBRX at USD 6.06, down 9.15%, BNGO at USD 1.00, down 9.09%, and FLNA at USD 0.44, down 8.71%, with varied Pluang order activity and hold times.
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
Cisco is set to report its fiscal Q1 2027 earnings with a focus on cloud growth and AI demand. Analysts expect revenue around $18.1 billion, operating income of $6.5 billion, and earnings per share of $1.33, reflecting strong year-over-year growth. T...
BASF has agreed to sell its global mining solutions business to SNF, a specialty chemical company based in France, following a strategic review of BASF's Performance Chemicals division. The deal includes BASF's mining chemicals portfolio, production ...
